2: Toripalimab Plus Celecoxib Improves pCR in dMMR Locally Advanced Colorectal Cancer
A phase 2 clinical trial published in The Lancet Oncology indicates that combining toripalimab with celecoxib improves pathological complete response in patients with dMMR or MSI-H colorectal cancer. The study suggests that COX-2 inhibition may enhance the efficacy of immune checkpoint blockade.
Why it matters
This research offers a potential new therapeutic strategy for patients with specific genetic subtypes of colorectal cancer who respond poorly to conventional chemotherapy.
Neoadjuvant immune checkpoint blockade has shown strong activity in mismatch repair-deficient or microsatellite instability-high locally advanced colorectal cancer. The PICC-2 trial evaluated whether adding the COX-2 inhibitor celecoxib to neoadjuvant toripalimab could further improve pathological complete response in this setting.
The report is a factual summary of a peer-reviewed medical study without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in